CS MEDICA A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.657 DKK | -2.35% |
|
+7.53% | +42.15% |
| Apr. 22 | CS Medica A/S Advances Global Reach with 180° Drug Store Alliance, Powered by Pull Market Strategy | CI |
| Apr. 12 | Transcript : CS Medica A/S, Q4 2023 Earnings Call, Apr 12, 2024 |
Valuation
| Fiscal Period: September | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 71.95 | 134.3 | 51.76 |
| Enterprise Value (EV) 1 | 63.68 | 132.4 | 60.95 |
| P/E ratio | 151 x | -17.1 x | -5.5 x |
| Yield | - | - | - |
| Capitalization / Revenue | 22.6 x | 12.7 x | 48.5 x |
| EV / Revenue | 20 x | 12.5 x | 57.1 x |
| EV / EBITDA | 53.4 x | -10.3 x | -3.5 x |
| EV / FCF | -8,706,246 x | -10,554,983 x | -15,245,934 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 4.06 x | 7.88 x | 7.68 x |
| Nbr of stocks (in thousands) | 10,902 | 12,323 | 12,323 |
| Reference price 2 | 8.996 | 15.95 | 6.492 |
| Announcement Date | 11/26/21 | 1/30/23 | 2/14/24 |
1DKK in Million2DKK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 1.426 | 2.111 | 3.18 | 10.58 | 1.067 |
| EBITDA 1 | 0.2111 | 0.496 | 1.191 | -12.86 | -17.42 |
| EBIT 1 | 0.1867 | 0.1115 | -0.176 | -13.33 | -17.9 |
| Operating Margin | 13.09% | 5.28% | -5.54% | -126% | -1,677.04% |
| Earnings before Tax (EBT) 1 | 0.0485 | -0.0318 | -0.4078 | -14.16 | -18.47 |
| Net income 1 | -0.1191 | -0.0546 | 0.6476 | -10.8 | -14.51 |
| Net margin | -8.35% | -2.59% | 20.37% | -102.08% | -1,359.8% |
| EPS | - | - | 0.0594 | -0.9303 | -1.180 |
| Free Cash Flow | - | -1.181 | -7.314 | -12.55 | -3.998 |
| FCF margin | - | -55.97% | -230.03% | -118.55% | -374.58% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/21/21 | 4/21/21 | 11/26/21 | 1/30/23 | 2/14/24 |
1DKK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | 3.92 | 2.93 | - | - | 9.19 |
| Net Cash position 1 | - | - | 8.28 | 1.89 | - |
| Leverage (Debt/EBITDA) | 18.54 x | 5.908 x | - | - | -0.5278 x |
| Free Cash Flow | - | -1.18 | -7.31 | -12.5 | -4 |
| ROE (net income / shareholders' equity) | - | 6.53% | 5.34% | -44% | -82.1% |
| ROA (Net income/ Total Assets) | - | 1.6% | -0.67% | -30.1% | -41.6% |
| Assets 1 | - | -3.414 | -96.68 | 35.85 | 34.87 |
| Book Value Per Share | - | - | 2.210 | 2.020 | 0.8500 |
| Cash Flow per Share | - | - | 0.9200 | 0.2400 | -0.0300 |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 4/21/21 | 4/21/21 | 11/26/21 | 1/30/23 | 2/14/24 |
1DKK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
- Stock Market
- Equities
- CSMED Stock
- Financials CS MEDICA A/S
